Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-glucosidase and pancreatic alpha-amylase are key digestive enzymes responsible for the breakdown of complex carbohydrates into glucose for absorption in the small intestine. Alpha-glucosidase acts on terminal, non-reducing alpha-1,4-linked residues in oligosaccharides, releasing free glucose, while pancreatic alpha-amylase acts primarily in the lumen to hydrolyze internal alpha-1,4 bonds, producing maltose and dextrins. Both are clinically relevant targets for the control of postprandial hyperglycemia in diabetes and are inhibited by drugs such as acarbose and miglitol to slow glucose absorption and blunt glycemic spikes. Deficiency of alpha-glucosidase (acid form) is implicated in Pompe disease, a lysosomal storage disorder.
Competitive inhibition of the enzyme active site to reduce carbohydrate digestion and glucose absorption, thereby blunting postprandial blood glucose spikes
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-Glucosidase & Pancreatic Alpha-Amylase.